Roscovitine is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM and shows little effect on CDK4/6.
Crizotinib is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectivley.
LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
Molidustat is a potent HIF-PH inhibitor with IC50 values of 480nM, 280nM and 450nM for PHD1, PHD2 and PHD3 (measured by the recombinant enzyme activity), respectively.
Pexidartinib is a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with IC50s of 20, 10, and 160 nM in vitro, respectively.
Defactinib is a potent FAK phosphorylation inhibitor and overcomes YB-1–mediated paclitaxel resistance by an AKT-dependent pathway.
Afuresertib is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively.
Vorasidenib is an isocitrate dehydrogenase (IDH) inhibitor.
Cabozantinib is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.
dBET6 is a degrader of BET bromodomain without directly affecting CDK9 localization.
CSN15827 Palbociclib Isethionate